<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262886</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000449939</org_study_id>
    <secondary_id>URCC-U1801</secondary_id>
    <secondary_id>URCC-RSRB-09084</secondary_id>
    <nct_id>NCT00262886</nct_id>
  </id_info>
  <brief_title>Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer</brief_title>
  <official_title>Non-Myeloablative HLA-Matched Sibling Allogeneic Peripheral Blood Stem Cell Transplantation for Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <brief_summary>
    <textblock>
      RATIONALE: A peripheral stem cell transplant or bone marrow transplant from a brother or&#xD;
      sister may be an effective treatment for kidney cancer.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well a donor peripheral stem cell or bone marrow&#xD;
      transplant works in treating patients with relapsed or refractory metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of nonmyeloablative sibling allogeneic peripheral blood stem cell&#xD;
           transplantation in patients with relapsed or refractory metastatic renal cell carcinoma.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
        -  Conditioning regimen: Patients receive cyclophosphamide IV on days -7 and -6 and&#xD;
           fludarabine IV on days -5 to -1. Patients receiving 5/6-mismatched cells also receive&#xD;
           anti-thymocyte globulin IV on days -5 to -3.&#xD;
&#xD;
        -  Allogeneic peripheral blood stem cell (PBSC) infusion: Patients undergo allogeneic PBSC&#xD;
           or bone marrow transplantation on day 0.&#xD;
&#xD;
        -  Graft-versus-host disease (GVHD) prophylaxis: Patients receive oral mycophenolate&#xD;
           mofetil twice daily on days 0-30. Patients receive tacrolimus IV continuously or orally&#xD;
           twice daily beginning on day -2 and continuing up to day 44-100 in the absence of GVHD.&#xD;
&#xD;
        -  Donor lymphocyte infusion: Patients with partial or complete T-cell chimerism receive up&#xD;
           to 3 donor lymphocyte infusions in the absence of GVHD or progressive disease.&#xD;
&#xD;
      After completion of study treatment, patients are evaluated periodically for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate based on tumor measurements at 1 year</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by NCI CTC at days 0, 7, 14, 21 and 28 after transplantation and monthly for 11 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and disease-free survival at day 100 and 1 year after transplantation</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>graft-versus-tumor induction therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic renal cell carcinoma&#xD;
&#xD;
               -  Relapsed or refractory disease&#xD;
&#xD;
               -  Tumor not amenable to complete surgical resection&#xD;
&#xD;
          -  No bone metastases only&#xD;
&#xD;
          -  No untreated brain metastases&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Available sibling donor who is HLA-identical or who has a mismatch at a single HLA&#xD;
             locus (i.e., a 6/6 or 5/6 match at the HLA-A, -B, and -DR loci)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 3 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 2 mg/dL&#xD;
&#xD;
          -  No untreated hypercalcemia&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF ≥ 40%&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  DLCO ≥ 40%&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  HIV-1 and -2 negative&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No other active malignancy except basal skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 15 days since prior treatment for renal cell carcinoma&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. J. Ifthikharuddin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>James P. Wilmot Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jane L. Liesveld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>James P. Wilmot Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>December 6, 2005</study_first_submitted>
  <study_first_submitted_qc>December 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2005</study_first_posted>
  <last_update_submitted>June 5, 2013</last_update_submitted>
  <last_update_submitted_qc>June 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2013</last_update_posted>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

